MAPK7 and neoplasm: Melanoma cells with BRAFV600E or wild type BRAF showed a reduction in tumour cell proliferation in vitro and tumour growth in xenograft models when using shRNA against ERK5 (Tusa et al., 2018), suggesting that ERK5 therapies could have benefit in tumours carrying either wild type BRAF or BRAFV600E mutations.